The services provided in Core C will enable this Program Project to incorporate highly needed histopathology services and innovative and powerful imaging technology into the program in a cost-effective manner. Core C supports every project within the program by providing access to sophisticated imaging technologies. Super-resolution imaging, 3-dimensional (3D) tissue reconstruction, live cell imaging in animals and whole animal imaging will strongly impact the Program during the next period of requested funding, and indeed has already begun to do so. Ongoing innovations by Core C will make these technologies powerful biological tools for the use in cancer research. Importantly, Core C also provides pathological support for the Program through a subcontract with a world-class pathologist. During the upcoming period of requested support, the core proposes to support Program investigators through four general aims. First, the program will provide assistance with histology, immune labeling and pathology. Second, the Core will support super-resolution imaging and live cell imaging using one of only about twenty OMX microscopes that exists worldwide. Third, the core will assist with imaging at the tissue level, either using 3D tissue reconstruction or live imaging in animals. These technologies each require custom built microscopes that are not generally available. Fourth, to provide Program investigators with tools to track tumor growth and metastasis, the Core will assist with whole animal imaging approaches, including bioluminescence, fluorescent proteins and small animal ultrasound. Together, the Core have an unprecedented imaging platform, covering super-resolution imaging, 3D tissue reconstruction, live cell tracking in tissues and whole animal imaging. A core that enables program investigators access to these technologies is essential as most of the imaging technologies supported by the Core are highly sophisticated and require very specialized training. Furthermore, access to the instruments required for these imaging technologies would be cost-prohibitive without the support of a core.
);Imaging is a mainstay of modern cancer research. Core C is at the leading edge of technology development and implementation of imaging in cancer research, from super resolution, to the tissue and whole animal level. Thus, work within the Core impacts not only the Program but also the broader community and the Core s committed to continue its innovations as it integrates with the Program.
|On, Kin Fan; Jaremko, Matt; Stillman, Bruce et al. (2018) A structural view of the initiators for chromosome replication. Curr Opin Struct Biol 53:131-139|
|Knott, Simon R V; Wagenblast, Elvin; Khan, Showkhin et al. (2018) Asparagine bioavailability governs metastasis in a model of breast cancer. Nature 554:378-381|
|Shamay, Yosi; Shah, Janki; I??k, Mehtap et al. (2018) Quantitative self-assembly prediction yields targeted nanomedicines. Nat Mater 17:361-368|
|Tramentozzi, Elisa; Ferraro, Paola; Hossain, Manzar et al. (2018) The dNTP triphosphohydrolase activity of SAMHD1 persists during S-phase when the enzyme is phosphorylated at T592. Cell Cycle 17:1102-1114|
|Arun, Gayatri; Diermeier, Sarah D; Spector, David L (2018) Therapeutic Targeting of Long Non-Coding RNAs in Cancer. Trends Mol Med 24:257-277|
|Tarumoto, Yusuke; Lu, Bin; Somerville, Tim D D et al. (2018) LKB1, Salt-Inducible Kinases, and MEF2C Are Linked Dependencies in Acute Myeloid Leukemia. Mol Cell 69:1017-1027.e6|
|Xu, Yali; Milazzo, Joseph P; Somerville, Tim D D et al. (2018) A TFIID-SAGA Perturbation that Targets MYB and Suppresses Acute Myeloid Leukemia. Cancer Cell 33:13-28.e8|
|Huang, Yu-Han; Klingbeil, Olaf; He, Xue-Yan et al. (2018) POU2F3 is a master regulator of a tuft cell-like variant of small cell lung cancer. Genes Dev 32:915-928|
|Livshits, Geulah; Alonso-Curbelo, Direna; Morris 4th, John P et al. (2018) Arid1a restrains Kras-dependent changes in acinar cell identity. Elife 7:|
|Tiriac, Hervé; Belleau, Pascal; Engle, Dannielle D et al. (2018) Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer. Cancer Discov 8:1112-1129|
Showing the most recent 10 out of 610 publications